Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Capivasertib - AstraZeneca

Drug Profile

Capivasertib - AstraZeneca

Alternative Names: AZD 5363

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astex Therapeutics; Cancer Research Technology; The Institute of Cancer Research
  • Developer Astex Therapeutics; AstraZeneca; Cancer Research Technology; Conquer Cancer Foundation; Royal Marsden NHS Foundation Trust; Samsung Medical Center; The Institute of Cancer Research; University of Nottingham; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Piperidines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Gastric cancer; Non-small cell lung cancer; Prostate cancer
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 18 Jun 2020 National Cancer Institute completes enrolment in a phase II MATCH-Subprotocol Y for Cancer (Late-stage disease) in USA (PO) (NCT04439123)
  • 29 May 2020 Efficacy and adverse events data from the phase I/II ProCAID trial in Prostate cancer presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)
  • 16 Apr 2020 Phase-III clinical trials in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in Spain, United Kingdom, USA (PO, Tablet) (NCT04305496) (EudraCT 2019-003629-78)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top